石药集团一项创新药研究成果入选2026年第10届国际头颈部肿瘤创新大会(ICHNO)

石药集团02-27 08:15

2026年3月19日至21日，第10届国际头颈部肿瘤创新大会(ICHNO)将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会(ESTRO)、欧洲头颈学会(EHNS)和欧洲肿瘤内科学会(ESMO)联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。石药集团将在本届ICHNO上首次披露一项在研产品的最新临床试验进展，这也是首次在ICHNO上披露B7H3靶点药物对鼻咽癌的疗效和安全性：B7-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614073003?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-27 08:15","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614073003","market":"hk","top_or_hot":-1,"title":"石药集团一项创新药研究成果入选2026年第10届国际头颈部肿瘤创新大会(ICHNO)","media":"石药集团","content":"<div>\n<p>2026年3月19日至21日，第10届国际头颈部肿瘤创新大会(ICHNO)将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会(ESTRO)、欧洲头颈学会(EHNS)和欧洲肿瘤内科学会(ESMO)联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。石药集团将在本届ICHNO上首次披露一项在研产品的最新临床试验进展，这也是首次在ICHNO上披露B7H3靶点药物对鼻咽癌的疗效和安全性：B7-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团一项创新药研究成果入选2026年第10届国际头颈部肿瘤创新大会(ICHNO)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团一项创新药研究成果入选2026年第10届国际头颈部肿瘤创新大会(ICHNO)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 08:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b><strong>石药集团</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2026年3月19日至21日，第10届国际头颈部肿瘤创新大会(ICHNO)将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会(ESTRO)、欧洲头颈学会(EHNS)和欧洲肿瘤内科学会(ESMO)联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。石药集团将在本届ICHNO上首次披露一项在研产品的最新临床试验进展，这也是首次在ICHNO上披露B7H3靶点药物对鼻咽癌的疗效和安全性：B7-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0880133367.SGD","symbol_name":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b","article_id":"2614073003","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022708273197a73604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614073003","pubTimestamp":1772151355,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2026年3月19日至21日，第10届国际头颈部肿瘤创新大会将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会、欧洲头颈学会和欧洲肿瘤内科学会联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。本临床研究结果显示SYS6043有望为晚期鼻咽癌提供一种新的治疗选择。SYS6043作为新一代B7-H3靶点ADC，此次在ICHNO大会上的亮眼数据表明其在鼻咽癌领域具有良好的抗肿瘤活性和持续缓解的能力，有望为晚期鼻咽癌后线治疗带来新的突破。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1191":"制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1161":"生物科技","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","01093":"石药集团","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1515":"抗疫概念","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK1574":"生物医药B类股","06978":"永泰生物-B","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"An innovative drug research result of CSPC was selected into the 10th International Conference on Head and Neck Oncology Innovation (ICHNO) in 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"06978":1.5},"content_text":"2026年3月19日至21日，第10届国际头颈部肿瘤创新大会(ICHNO)将在西班牙塞维利亚召开，ICHNO由欧洲放射治疗与肿瘤学学会(ESTRO)、欧洲头颈学会(EHNS)和欧洲肿瘤内科学会(ESMO)联合主办，是宣传推动多学科头颈部肿瘤学发展的国际盛会。石药集团将在本届ICHNO上首次披露一项在研产品的最新临床试验进展，这也是首次在ICHNO上披露B7H3靶点药物对鼻咽癌的疗效和安全性：B7-H3 ADC SYS6043SYS6043在晚期实体瘤I期临床研究-鼻咽癌患者结果：最新突破摘要的口头报告（LBA Proffered paper）摘要编号：574报告题目：Safety and efficacy of SYS6043, a novel B7-H3 targeting antibody-drug conjugates, in patients with advanced nasopharyngeal carcinoma报告日期：2026年3月19日 14:30 CET该项研究是由中山大学肿瘤防治中心张力教授和中国医学科学院肿瘤医院吴令英教授共同牵头开展的一项多中心、开放性I期临床试验，旨在评估SYS6043在晚期实体瘤患者中的有效性和安全性。主要研究终点为安全性、耐受性和RP2D。本临床研究结果显示SYS6043有望为晚期鼻咽癌提供一种新的治疗选择。SYS6043为石药集团巨石生物制药有限公司开发的一款靶向 B7-H3 的抗体偶联药物（ADC）。其抗体部分可特异性结合到表达B7-H3的细胞表面并内化入细胞，Linker-Drug为四肽连接子GGFG偶联拓扑异构酶Ⅰ抑制剂，蛋白酶特异性剪切可释放小分子毒素对肿瘤细胞进行杀伤，且发挥旁观者效应非特异性杀伤周围肿瘤组织细胞。与传统野生型Fc不同，SYS6043废除了FcγR结合活性，可减少FcγR介导的淋巴细胞摄取，降低脱靶毒性风险，提高治疗安全性。根据世界卫生组织（WHO）公布的2022年统计数据，全球范围内年新诊断鼻咽癌12.0万例，死亡7.3万例。据国家癌症中心公布的同年度数据，我国鼻咽癌新发病例数5.1万例，死亡2.8万例，其中男性发病率约30/10万，女性发病率约13/10万，男性的发病率约为女性的2.3倍。当前，对于晚期、复发转移的鼻咽癌患者，有限的治疗模式及高复发率往往导致预后较差，患者生存亟待改善。SYS6043作为新一代B7-H3靶点ADC，此次在ICHNO大会上的亮眼数据表明其在鼻咽癌领域具有良好的抗肿瘤活性和持续缓解的能力，有望为晚期鼻咽癌后线治疗带来新的突破。【声明】1、本新闻旨在分享研究进展信息，非广告用途；2、本资料仅供医药专业人士参考，非产品推荐依据，也不应被视为诊疗建议。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614073003","isCrawlerRequest":true}